Liquidia Corporation

LQDA· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

$83.85-0.31%

2026-08-03

Financials

Valuation Metrics

Liquidia Corporation's Market Cap is $7.46B. At end of 2025 it was $3.00B. Ranked #1125 of 3,112 in US market (top 36%), #369 of 1,445 on NASDAQ (top 26%), #60 of 269 in Pharmaceuticals, Biotechnology & Life Sciences (top 22%) by Market Cap.

Investment Metrics(as of 2026-08-03)

Metric	Value	Rank
Size
Market Cap	$7.46B	US#1,125/3,112 Sec#60/269
Revenue	$288M	US#2,574/3,112 Sec#100/269
Net Income	$22M	US#2,053/3,112 Sec#68/269
Total Assets	$402M	US#2,825/3,112 Sec#184/269
Net Assets	$109M	US#2,869/3,112 Sec#224/269
Value
P/E	334.30x	US#2,182/3,112 Sec#73/269
P/B	68.67x	US#2,946/3,112 Sec#254/269
P/S	25.89x	US#2,840/3,112 Sec#154/269
EV/EBITDA	137.91x	US#2,452/3,112 Sec#85/269
FCF Yield	0.55%	US#2,185/3,112 Sec#81/269
Profitability
ROE	20.54%	US#557/3,112 Sec#38/269
ROA	5.55%	US#916/3,112 Sec#50/269
Op. Margin	15.81%	US#1,183/3,112 Sec#49/269
Revenue Growth	4158.49%	US#13/3,112 Sec#4/269
Financial Health
Debt Ratio	269.81%	US#2,036/3,112 Sec#215/269
Total Debt	$185M	US#2,219/3,112 Sec#98/269
FCF	$41M	US#1,993/3,112 Sec#73/269
Cash	$223M	US#1,647/3,112 Sec#105/269
Current Ratio	2.22x	US#1,125/3,112 Sec#217/269
Net Debt/EBITDA	-0.71x	US#380/3,112 Sec#24/269
Performance
1Y Return	374.26%	US#43/3,112 Sec#17/269
1M Return	6.23%	US#839/3,112 Sec#33/269
From 52W High	-7.96%	US#860/3,112 Sec#40/269
1Y MDD	-35.66%	US#1,728/3,112 Sec#116/269
Trading
Volume	1,080,185 shares	US#1,409/3,112 Sec#139/269
Trading Value	$89M	US#996/3,112 Sec#60/269
Per Share
EPS	$-0.79	US—/3,112 Sec—/269
BPS	$0.51	US#2,678/3,112 Sec#218/269